Oncology
Develops and sells medicines used to treat certain cancers, especially in areas like prostate cancer and neuroendocrine tumors.
Customers and revenue model
Ipsen SA
PAR:IPN
Ipsen SA
PAR:IPN
Price:
158.7
EUR
-0.44%
Market Closed
Market Cap:
€13.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Ipsen SA
PAR:IPN
|
FR |
|
Ageas SA
OTC:AGESF
|
BE |
|
Atlas Arteria Group
ASX:ALX
|
AU |
|
B
|
Blu Label Unlimited Group Ltd
JSE:BLU
|
ZA |
|
Aym Syntex Ltd
BSE:508933
|
IN |
|
88 Energy Ltd
ASX:88E
|
AU |
|
O
|
Orkla ASA
DUS:OKL
|
NO |
|
Mettler-toledo International Inc
NYSE:MTD
|
US |
|
Realty Income Corp
NYSE:O
|
US |
|
OneSpaWorld Holdings Ltd
NASDAQ:OSW
|
BS |
|
Ramsdens Holdings PLC
LSE:RFX
|
UK |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Headquarters
- France FR
- Employees
- 5 535
- IPO date
- Dec 6, 2005
Ipsen is a French specialty pharmaceutical company that develops and sells prescription medicines for serious diseases, especially in oncology, rare diseases, and certain neurological conditions. Its business is built around branded drugs that doctors prescribe in hospitals and clinics, rather than over-the-counter products.
The company makes money by selling these medicines to hospitals, healthcare providers, and pharmaceutical distributors around the world. It also relies on partnerships and licensing deals in some areas of research and commercialization, which helps it bring products to market without doing every step alone.
What makes Ipsen different is its focus on a narrower set of hard-to-treat diseases where patients need specialized care and long-term treatment. That gives it a role as a focused drug maker: it does not try to be a broad consumer health company, but instead sells targeted therapies in niche medical markets where scientific expertise and physician trust matter most.
Continue IPN Research
Other Ipsen SA listings:
